Butyric Acid

Butyric Acid

SCHEMBL8712901

CCCC(=O)O.CCN(CC)CC.ClC(Cl)Cl

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.59
HDAC3 O15379 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
AKR1B1 P15121 1/20 0.41
KDM5A P29375 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
GPR84 Q9NQS5 7/20 0.39
PPARG P37231 7/20 0.39
PPARD Q03181 7/20 0.39
PPARA Q07869 7/20 0.39
HDAC11 Q96DB2 5/20 0.39
TSHR P16473 5/20 0.39
PTPN1 P18031 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TLR2 O60603 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FABP4 P15090 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL834319 0.91 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL4253065 0.88 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL5477656 0.88 FFAR3 (0.68) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL8517702 0.88 FFAR3 (0.68) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL315107 0.88 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL5904081 0.86 FFAR3 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL9486329 0.86 FFAR3 (0.65) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL7629511 0.85 FFAR3 (0.72) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL10429532 0.84 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL618898 0.84 FFAR3 (0.62) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512162-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides ASED, LLC (US) 2016-12-06 US disclosed
US-9493773-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2016-11-15 US disclosed
US-20150252071-A1 Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides ASED, LLC 2015-09-10 US disclosed
US-9045521-B2 Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2015-06-02 US disclosed
US-20150119565-A1 SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES ASED, LLC 2015-04-30 US disclosed
US-8859754-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2014-10-14 US disclosed
US-20140039175-A1 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides ASED, LLC 2014-02-06 US disclosed
US-5750666-A FOR SYNTHESIZING NEW MONONUCLEOTIDES AND POLYNUCLEOTIDES HAVING PHOSPHOROTHIOATE AND PHOSPHORODITHIOATE INTERNUCLEOTIDE LINKAGES COMPETITVE TECHNOLOGIES, INC. (US) 1998-05-12 US disclosed
US-5684148-A NUCLEOSIDES AND POLYNUCLEOTIDES AS FLUORESCENT AGENTS FOR MEDICAL DIAGNOSIS COMPETITIVE TECHNOLOGIES, INC. (US) 1997-11-04 US disclosed
US-5602244-A DINUCLEOSIDE PRECURSORS IN OLIGONUCLEOTIDE SYNTHESIS; USEFUL AS ANTISENSE INHIBITORS OF TRANSLATION COMPETITIVE TECHNOLOGIES, INC. (US) 1997-02-11 US disclosed
US-5218103-A Nucleoside thiophosphoramidites UNIVERSITY PATENTS, INC. (US) 1993-06-08 US disclosed
EP-0378615-A4 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES 1992-04-08 EP disclosed
WO-1991004983-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1991-04-18 WO disclosed
EP-0378615-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES COMPETITIVE TECHNOLOGIES INC. (US) 1990-07-25 EP disclosed
WO-1989011486-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1989-11-30 WO disclosed
US-4476301-A Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1984-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140039175-A1 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides NSUN3, RNGTT, DUT FFAR3 3252/4885HDAC3 1321/4885HDAC1 2575/4885
US-20150252071-A1 Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides NSUN3, DUT, RNGTT FFAR3 3182/4885HDAC3 1167/4885HDAC1 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.